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abstract: Heterodimeric hCG is one of the key hormones determining early pregnancy success. We have previously identiﬁed rare
missense mutations in hCGb genes with potential pathophysiological importance. The present study assessed the impact of these mutations
on the structure and function of hCG by applying a combination of in silico (sequence and structure analysis, molecular dynamics) and in vitro
(co-immunoprecipitation, immuno- and bioassays) approaches. The carrier status of each mutation was determined for 1086 North-
Europeans [655 patients with recurrent miscarriage (RM)/431 healthy controls from Estonia, Finland and Denmark] using PCR-restriction
fragment length polymorphism. The mutation CGB5 p.Val56Leu (rs72556325) was identiﬁed in a single heterozygous RM patient and caused
a structural hindrance in the formation of the hCGa/b dimer. Although the amount of the mutant hCGb assembled into secreted intact
hCG was only 10% compared with the wild-type, a stronger signaling response was triggered upon binding to its receptor, thus compensating
the effect of poor dimerization. The mutation CGB8 p.Pro73Arg (rs72556345) was found in ﬁve heterozygotes (three RM cases and two
control individuals) and was inherited by two of seven studied live born children. The mutation caused  50% of secreted b-subunits to
acquire an alternative conformation, but did not affect its biological activity. For the CGB8 p.Arg8Trp (rs72556341) substitution, the
applied in vitro methods revealed no alterations in the assembly of intact hCG as also supported by an in silico analysis. In summary, the
accumulated data indicate that only mutations with neutral or mild functional consequences might be tolerated in the major hCGb genes
CGB5 and CGB8.
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Introduction
Placental chorionic gonadotrophin (hCG) is a pleiotropic hormone
that functions since early pregnancy in an endocrine/autocrine/para-
crine way to support progesterone production by the corpus
luteum, to promote angiogenesis (Zygmunt et al., 2002), trophoblast
invasiveness (Guibourdenche et al., 2010) and decidualization of the
endometrium (Zimmermann et al., 2009; Kajihara et al., 2010), to
stimulate fetal testicular testosterone production (Huhtaniemi et al.,
1977) and regulate maternal immunotolerance (Kayisli et al., 2003;
Tsampalas et al., 2010). hCG is produced already by an 8-cell blasto-
cyst prior to implantation and its concentration doubles every 2 days
until peaking at gestational weeks 9–11 (Hay, 1988; Lopata and Hay,
1989). Large inter-individual variation in the levels of hCG during preg-
nancy has been documented and critically low amounts in maternal
circulation may indicate an adverse pregnancy outcome (Korhonen
et al., 1994; Rull and Laan, 2005).
Like all heterodimeric glycoprotein hormones (LH, FSH, TSH), hCG
is formed by non-covalent association of the common a-subunit and
the hormone-speciﬁc b-subunit (Morgan et al., 1975). The crystal
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Advanced Access publication on May 3, 2012 doi:10.1093/molehr/gas018structure of hCG has revealed a similar tertiary structure for both
subunits, which are composed of three hairpin loops held together
by three disulﬁde bonds that form a characteristic cystine knot
structure (Lapthorn et al., 1994). The integrity of the cystine knot is
essential for the folding, assembly and function of the hormone.
The structural and functional properties of the subunits are deter-
mined by six cystine bonds and six oligosaccharide chains (two
N-linked, four O-linked) in hCGb and ﬁve cystine bonds and two
N-linked carbohydrates in the a-subunit (Morgan et al., 1975;
Lapthorn et al., 1994).
The chorionic gonadotrophin beta (CGB) genes encoding the hCG
b-subunit (145 aa) have evolved in the primate lineage by serial dupli-
cations of the ancestral LH b-subunit coding gene (LHB)( Maston and
Ruvolo, 2002; Hallast et al., 2008; Nagirnaja et al., 2010). In humans,
the common gene cluster for LHB and six CGB genes is located at
19q13.32 (Policastro et al., 1986). Four genes (CGB, CGB5, CGB7
and CGB8) code for an almost identical hCGb protein in the placenta,
but have a highly variable transcriptional activity (Miller-Lindholm et al.,
1997; Rull and Laan, 2005; Rull et al., 2008a). A normal uncomplicated
pregnancy is characterized by a balanced biallelic expression of the
maternal and paternal alleles of the hCGb genes (Uusku ¨la et al., 2010).
Addressing the genetic variation of CGB genes has been challenging
due to a high DNA sequence similarity (up to 99%) between gene
copies (Hallast et al., 2005). So far, only one naturally occurring
variant of hCGb (CGB5 p.Val79Met) has been functionally character-
ized leading to an inefﬁcient hCG assembly in vitro (Miller-Lindholm
et al., 1999). The p.Val79Met heterozygotes represented 14/334
(4.2%) of the studied random subjects from Omaha, NE, USA but
no clinical information was available on the mutation carriers. Curi-
ously, this substitution was totally absent in further screening of over
500 DNA samples from ﬁve European populations (Jiang et al., 2004).
We have recently identiﬁed heterozygous cases of novel missense
mutations in the most actively transcribed hCGb genes (CGB5, CGB8)
in Estonian and Finnish samples with recurrent miscarriage (RM) (Rull
et al., 2008b). RM affects up to 3% of fertile couples aiming to conceive
a child and around half are deﬁned as idiopathic (Bricker and Farquhar-
son, 2002; Rai and Regan, 2006).The reported substantial familiar dis-
position to RM points to the contribution of genetic risk factors
(Christiansen et al., 1990; Kolte et al., 2011). This current study
addressed the prevalence of the identiﬁed hCGb mutations in a
larger Northern Europe sample set (total n ¼ 1086 subjects; 655 RM
cases and 431 fertile controls) and assessed their effect on the
structure and function of the synthesized hCG hormone using in silico
and in vitro approaches. The study showed that the CGB5 p.Val56Leu
mutation substantially affects the assembly and functionality of intact
hCG a/b heterodimers, the CGB8 p.Pro73Arg substitution alters the
conformation of the hCGb-subunit, while the CGB8 p.Arg8Trp is
neutral in the structural and functional context.
Materials and Methods
Identiﬁcation of subjects with CGB5
p.Val56Leu, CGB8 p.Arg8Trp and
p.Pro73Arg mutations
This study was approved by the Ethics Review Committee on Human
Research of the University of Tartu, Estonia, Ethics Committee of the
Department of Obstetrics and Gynecology, Helsinki University Central
Hospital outpatient clinic for women with RM and the Ethics Committee
of the Fertility Clinics, Rigshospitalet, Copenhagen, Denmark. The study
was conducted according to the Declaration of Helsinki principles. A
written informed consent to participate in the study was obtained from
each individual prior to recruitment.
Details of the initial identiﬁcation of mutations in the hCGb coding genes
in Estonian and Finnish couples with RM have been published previously
(Rull et al., 2008b). Brieﬂy, subjects had been recruited at the Women’s
Clinic of Tartu University Hospital and Nova Vita Clinic, Tallinn, Estonia
during 2003–2007; and at the Department of Gynecology and Obstetrics
of the Helsinki University Hospital in Finland during 2001–2004. As mater-
nally and paternally derived hCGb gene variants contribute equally to the
function of the fetal genome, the patient group included both the female
and male partner of the couples experiencing idiopathic RM (≥3 consecu-
tive miscarriages during the ﬁrst trimester of pregnancy without any iden-
tiﬁed cause; age 18–40 years). Mutation screening was performed by
resequencing the CGB5 and the CGB8 genes in 205 RM patients (82
couples, 41 single females) and 195 age-matched fertile women with no
history of miscarriages, and either at least one (Finnish subjects) or
three (Estonian subjects) successful pregnancies (Rull et al., 2008b). The
screening led to the identiﬁcation of CGB5 p.Val56Leu (rs72556325;
g.1178G . C, position on the genomic sequence relative to mRNA
start site), CGB8 p.Arg8Trp (rs72556341; g.806C . T) and p.Pro73Arg
(rs72556345; g.1237C . G) mutations.
The current study addressed the presence of the three hCGb
gene mutations in an extended RM case–control sample from Denmark
(n ¼ 686). The Danish subjects have been recruited since 1986 at the
Danish Recurrent Miscarriage Clinics, Copenhagen and Aalborg,
Denmark: 450 RM patients (199 RM couples, 52 single patients; age
20–41 years) with ≥3 consecutive miscarriages before gestational week
20 (.95% during the ﬁrst trimester) and 236 fertile controls (117
couples and 2 single females) with no history of miscarriages and at
least two successful pregnancies. Mutational screening for the three
hCGb mutations (CGB5 p.Val56Leu, CGB8 p.Arg8Trp and p.Pro73Arg)
was performed on genomic DNA using either PCR and allele-speciﬁc
restriction fragment length polymorphism (RFLP) (CGB5), or a combin-
ation of long-range and nested PCR followed by RFLP (CGB8)( Rull
et al., 2008b) (primers in Table I). Allele-speciﬁc restriction of ampliﬁed
PCR products was performed with FastDigest
wAlwNI (CaiI) (Thermo
Fisher Scientiﬁc, Fermentas, Vilnius, Lithuania) for CGB5 p.Val56Leu and
a combination of NcoI, PdiI and DraI (Fermentas) for mutual restriction
analysis of CGB8 p.Arg8Trp and p.Pro73Arg (Supplementary data, Fig.
S1). All mutation carriers identiﬁed by RFLP were conﬁrmed by direct
sequencing.
In total, the screening of CGB5 p.Val56Leu, CGB8 p.Arg8Trp and
p.Pro73Arg mutations among Northern Europeans was performed in
655 RM patients (281 couples, 93 single patients) and 431 fertile controls
with no documented history of RM (117 couples, 197 single patients). In all
analyzed RM cases, clinical risk factors known to increase the risk of RM
had been excluded. All patients had a normal karyotype tested from peri-
pheral blood lymphocyte cultures. Female patients had normal menstrual
cycles and no uterine anomalies (by ultrasonography or hystero-
sonogram) or antiphospholipid syndrome. Additionally, the female patients
were screened for the presence of thrombophilic mutations [Factor V
Leiden, p.Arg506Gln, rs6025 (Bertina et al., 1994); F2, prothrombin
G20210A; rs1799963 (Poort et al., 1996)].
The DNA of live born children of mutation carriers was analyzed in
order to assess the inheritance of studied mutations (Table II). Altogether
nine children (two from a couple with the CGB8 p.R8W carrier and seven
from couples with the CGB8 p.P73R carriers) were available for genotyp-
ing, performed as described above.
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analysis
To explore the evolutionary constraints on hCGb amino acid positions
Arg8, Val56 and Pro73, homologs of hCGb were searched using BLAST
(Altschul et al., 1997) with the hCGb sequence against the National
Center for Biotechnology Information (NCBI) non-redundant protein se-
quence database (ftp://ftp.ncbi.nih.gov/blast/db). Homologs with over
90% sequence identity to each other were excluded. The resulting 37
homologous protein sequences were aligned with ClustalW2 (http
://www.ebi.ac.uk/Tools/msa/clustalw2/) to the protein sequence corre-
sponding to the mature human hCGb peptide (homology region 1–111
aa; Supplementary data, Table SI and Fig. S2). The sequence of the ana-
lyzed mature hCGb protein does not include the signal peptide (20 aa;
codons –1 up to –20) of the full precursor protein (165 aa). Positional
variability was assessed by the analysis of sequence logos generated
using WebLogo (Crooks et al., 2004).
Structuralanalysis of amino acidchanges in the hCGb-subunit was based
on the hCG crystal structure (1hcn) obtained from the Protein Data Bank
(www.pdb.org). The fraction of solvent accessible surface (SAS) of a given
amino acid in either the isolated hCGb-subunit or the hCGa/b complex
was calculated with Voroprot (Olechnovic ˇ et al., 2011) as the following
ratio: (SAS of Ca and a side-chain in the context of the protein 3D struc-
ture)/(SAS of Ca and a side-chain of the isolated residue).
Molecular dynamics simulations
Molecular dynamics (MD) simulations of the hCG heterodimeric assem-
blies containing either the wild-type or one of the three mutant hCG
b-subunits were performed using GROMACS package, versions 4.5.3
and 4.5.5 (Hess et al., 2008). GROMOS 43a1 united atom force ﬁeld
(van Gunsteren et al., 1996) was employed to model protein atoms.
The protein was immersed into a cubic box extending at least by
0.9 nm from the protein. The rest of the box was ﬁlled with explicit
simple point charge water molecules. Chloride ions were added to neu-
tralize the charge of the protein and periodic boundary conditions were
imposed for the simulations. Prior to running the simulation, the system
was minimized for 1000 steepest descent iterations and then equilibrated
for 20 ps with non-hydrogen protein atoms restrained.
During the simulations, a Berendsen pressure coupling with time con-
stant t ¼ 0.5 ps, and a temperature coupling using velocity rescaling
with stochastic term (t ¼ 0.1 ps) were applied. Long range electrostatic
.............................................................................................................................................................................................
Table I Primer sequences used in the study.
Primer name Sequence 5′-3′ Product length
I. PCR ampliﬁcation for genotyping p.Arg8Trp, p.Val56Leu and p.Pro73Arg mutations by RFLP
Ampliﬁcation of CGB5 gene
CGB5_F CAGGAAAGCCTCAAGTAGAGGAG 1757 bp
CGB5_R CGCTCGACGATGTTTTCTATTTT
Ampliﬁcation of CGB8 gene
CGB8_F CACGCCTGTAATTGTCGGAGGCTGT 8384 bp
CGB8_R GAAAAGAGAGTGAAGATGGGGGACGAC
CGB8nested_F CCCGGATAACTTTTCGTATTTTTA 2544 bp
CGB8nested_R TCCTCAGATCAACTCTCATGGAT
II. PCR ampliﬁcation and site-directed mutagenesis for hCGb plasmid construction
Ampliﬁcation of hCGb coding region
CGB_coding_F CACCAAGGATGGAGATGTTCC 523 bp
CGB_coding_R TGCGGATTGAGAAGCCTTTA
Mutagenesis
a
Mut_CGB5_V56L_F GCCCTGCCTCAGGTGCTGTGCAACTACCGCG
Mut_CGB5_V56L_R CGCGGTAGTTGCACAGCACCTGAGGCAGGGC
Mut_CGB8_R8W_F GCCGCTTCGGCCATGGTGCCGCCCCATC
Mut_CGB8_R8W_R GATGGGGCGGCACCATGGCCGAAGCGGC
Mut_CGB8_P73R_F CTCCCTGGCTGCCGGCGCGGCGTGAAC
Mut_CGB8_P73R_R GTTCACGCCGCGCCGGCAGCCAGGGAG
III. PCR ampliﬁcation for the hCGa + b joint plasmid construction and production of ‘high yield’ hCG
b
Ampliﬁcation of hCGa coding region
CGA_coding_F CGTACGAGCGCCATGGATTA (Pﬂ23II) 369 bp
CGA_coding_R ACCGGTTTAAGATTTGTGATAATA (BshTI)
Ampliﬁcation of FLAG-tagged hCGb coding region
CGB_plasmid_F TTCGAACACCAAGGATGGA (Bsp119I) 551 bp
CGB_plasmid_R ATTAATTTACTTATCATCATCATCT (VspI)
aMutagenesis site is underlined.
bRestriction sites are indicated in italics and respective restriction enzymes given in brackets.
Analysis of hCGb mutations 381interactions were calculated using Fast Particle-mesh Ewald electrostatic
summation (Darden et al., 1993) with a 0.9 nm cutoff between the
short- and long-range interactions. A 1.4 nm cutoff was used for van der
Waals interactions. An all-bond constraint was imposed during the simu-
lation using the LINCS algorithm (Hess et al., 1997). The averaged MD
structures were subjected to 400 steps of steepest descents optimization,
followed by 3000 conjugated gradient minimization steps in vacuo. The sec-
ondary structures of a- and b-subunits were analyzed with the DSSP
program (Kabsch and Sander, 1983).
Plasmid construction and site-directed
mutagenesis for the analysis of hCG assembly
pM
2-hCGaplasmidcontaining hCGa-subunit2.4 kbminigene(Matzukand
Boime, 1988) was used for transient expression of the hCG a-subunit. For
the construction of the reference wild-type hCG b-subunit plasmid, the full
hCGb coding region (identical for CGB5 and CGB8) was ampliﬁed from
placental cDNA of a normal pregnancy (cDNA kindly provided by
Dr Jaana Ma ¨nnik) (Supplementary data, Fig. S3). The ampliﬁed DNA frag-
ment including natural hCGb initiation and stop codons was ligated into a
pcDNA3.1D/V5-His-TOPO plasmid (Invitrogen, Paisley, UK) and the
construct was veriﬁed by sequencing.
The plasmid containing the entire coding region of wild-type CGB5/
CGB8 genes was used as a template for the introduction of single base
pair mutations g.806C . T, g.1178G . C and g.1237C . G leading to
the amino acid substitutions p.Arg8Trp, p.Val56Leu and p.Pro73Arg, re-
spectively (Supplementary data, Fig. S3). Primers for site-directed muta-
genesis (Table I) were designed using the PrimerX software (http://
www.bioinformatics.org/primerx/) and mutagenesis was performed
employing a QuickChange Site-Directed Mutagenesis Kit (Stratagene, La
Jolla, CA, USA) as per the manufacturer’s instructions. Mutations were
veriﬁed by sequencing.
FLAG-tagged hCGb isoforms were constructed by the insertion of a
FLAG epitope in frame in front of the natural TAA STOP-codon of the
CGB5/CGB8 coding region involving either a p.Arg8Trp, p.Val56Leu or
p.Pro73Arg mutation. FLAG insertion was validated by sequencing. The C-
terminal tagging of a gonadotrophin b-subunit has been demonstrated not
to have an effect on the heterodimer assembly or the receptor binding
(Sugahara et al., 1995; Wu et al., 1996; Garcia-Campayo and Boime,
2001; Kottler et al., 2010).
hCG expression for the analysis of hCG
assembly
The Chinese hamster ovary (CHO) cells (American Type Culture Collec-
tion) were maintained in T75 ﬂasks in Dulbecco’s Modiﬁed Eagle Medium
(DMEM) with an F12 nutrient mixture and supplemented with 10% fetal
bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin (Sigma,
Dorset, UK). Cells were transiently co-transfected with the pM
2-hCGa
and either wild-type or one of the mutated hCGb plasmids using the Lipo-
fectamine 2000 reagent (Invitrogen) according to the manufacturer’s
protocol. Four to six hours after transfection, the medium was replaced
with the HyClone CHO Utility medium (Thermo Scientiﬁc, Waltham,
MA, USA) without antibiotics. The media were collected 48 h after trans-
fection and either stored at 2808C for immunoassays or immediately
used for co-immunoprecipitation.
Co-immunoprecipitation of FLAG-tagged
hCG for the analysis of hCG assembly
Priortoco-immunoprecipitation,thecollectedmediawereconcentratedby
centrifugation using Amicon Ultra-15 10-K ﬁlter devices (Millipore, Billerica,
MA, USA) according to the manufacturer’s instructions. To ensure an equal
protein concentration input into the co-immunoprecipitation reaction, the
total protein in the concentrated medium was determined using a protein
assay kit (Bio-Rad, Hercules, CA, USA), and 250 mg of total protein of
each sample was used for precipitation. Each FLAG-tagged hCGb variant
andassociatedhCGawasprecipitatedusinganti-FLAGantibodyconjugated
beads and the FLAG-Tagged Protein Immunoprecipitation Kit (Sigma) as
per the manufacturer’s instructions. Binding was conducted overnight at
.............................................................................................................................................................................................
Table II Carriers of the hCGb missense mutations
a and their pregnancy history.
Mutation Carrier
nationality
Disease
status
b
Mutation
carrier
b
No. of
miscarriages
c
No. of
children
c
No. of genotyped
children
Children with
mutation
p.R8W
(rs72556341)
Estonian
d RM Male partner 5 2 2 1
p.V56L
(rs72556325)
Finnish
d RM Male partner 3 1 n.a. n.a
p.P73R
(rs72556345)
Estonian
d RM Female partner 4 + 2 (ﬁrst, second
partner)
3 (second
partner)
e
10
Danish RM Female partner 3 2 2 0
Danish RM Male partner 9 (ﬁrst partner) 1 (second
partner)
n.a. n.a
Danish Fertile
control
Male partner 0 2 2 1
Danish Fertile
control
Male partner 0 2 2 1
n.a., DNA not available.
aIn total 1086 individuals were screened, including 655 RM cases and 431 fertile controls from Estonia, Finland and Denmark.
bDetailed clinical information of mutation carriers is provided in ‘Materials and Methods’ section and Supplemental data, Text S2.
cNumber of miscarriages and live births in a couple with same partners or indicated if otherwise.
dDiscovery mutation carriers reported in Rull et al. (2008b).
ePreterm deliveries (2910 g, gestational week 36; 2488 g, gestational week 37; 2428 g, gestational week 35).
382 Nagirnaja et al.48C and bound FLAG-tagged complexes were eluted under native condi-
tions using the 3× FLAG peptide.
Sodium dodecyl sulfate–polyacrylamide gel
electrophoresis and western blotting of
co-immunoprecipitated hCG complexes
Equal volumes (20 ml) of co-immunoprecipitated FLAG-tagged samples
were resolved on 4–12% gradient NuPAGE Bis-Tris polyacrylamide gels
(Invitrogen) under reducing or non-reducing conditions. Under reducing
conditions 10% 2-mercaptoethanol was added to the lithium dodecyl
sulfate sample buffer (Invitrogen) and samples were denatured at 958C
for 5 min. Under non-reducing conditions, samples were run in the
absence of 2-mercaptoethanol and heat denaturation as this has previously
been shown to cause dissociation of the hCG dimers (Ben-Menahem et al.,
1999). Formolecular weight estimation SeeBlue Plus2 Pre-StainedStandard
(Invitrogen) was added on each gel. The separated proteins and protein
complexes were transferred to nitrocellulose membranes (Invitrogen) for
western blotting. The membranes were blocked with 5% non-fat dry milk
for 1 h and then incubated overnight at 48C either in anti-FLAG antibody
(1:5000 dilution; Sigma) for the detection of the both heterodimeric and
free FLAG-tagged hCGb or in antiserum to human gonadotrophin a-
subunit (1:500 dilution; NHPP-NIDDK, Torrance, CA, USA) for detection
ofco-immunoprecipitatedhCGa-subunit,andthereforeanintacthCGhet-
erodimer only. The membrane was then incubated for 1.5 h at room tem-
perature in appropriate horse-radish peroxidase conjugated secondary
antibody (1:10 000 dilution; DAKO, Glostrup, Denmark). Chemilumines-
cencewasprobedusingtheECLPlusorECLPrimereagent (GEHealthcare,
Buckinghamshire, UK) and detected using an X-ray ﬁlm (GE Healthcare).
Three independent transfections and sodium dodecyl sulfate–polyacryl-
amide gel electrophoresis (SDS–PAGE) experiments were performed for
each mutant.
Immunoassays of heterodimeric hCG and
hCG b-subunits
The concentration of the assembled intact hCG was measured with an
hCG Human ELISA Kit (Abcam, Cambridge, MA) following the manufac-
turer’s instructions (detection limit ,50 pg/ml). The concentration of the
total hCGb was determined with an hCG + b kit on Roche Elecsys 1010
system (in Tartu University Hospital, Tartu, Estonia) with a detection limit
of ,0.1 mIU/ml and using the same aliquots of media as in the hCG
ELISA assay. Two independent transfection experiments with duplicate
reactions for each hCGb variant were performed for hCG expression
and analysis of hCG assembly.
Plasmid construction and production of ‘high
yield’ hCG for estimating hCG bioactivity and
glycosylation
To acquire a high yield of hCG for the bioassay and the enzymatic deglyco-
sylation assay, hCGa and FLAG-tagged hCGb coding regions were cloned
into a mutual expression vector pQMCF-CMV-RSVLTR and expressed
using the QMCF Technology (Silla et al., 2005) (Icosagen Cell Factory
OU ¨) (Supplementary data, Text S1). The full coding sequence of hCGa
(CGA gene) was ampliﬁed from the placental cDNA of a normal pregnancy
(cDNA kindly provided by Dr Jaana Ma ¨nnik) and hCGb from the
pcDNA3.1D/V5-His-TOPO plasmid containing either the wild-type or
mutated (p.Arg8Trp, p.Val56Leu or p.Pro73Arg) FLAG-tagged CGB5/
CGB8 coding region. PCR ampliﬁcation was performed using primers
listed in Table I and HOT FIREPol DNA polymerase (Solis BioDyne,
Tartu, Estonia) according to the manufacturer’s instructions. The cDNA
variants of both hCG subunits were subsequently cloned into the
pQMCF-CMV-RSVLTR vector (Icosagen Cell Factory OU ¨) containing two
expression cassettes. The construct was veriﬁed bysequencing. Additional-
ly, wild-type hCGb and hCGa were separately cloned into the
pQMCF-CMV-RSVLTR expression vector for the production of respective
monomers used as negative controls in the bioassay of hCG function.
For high-yield production of hCG variants a CHO-based cell line
CHOEBNALT85 (Icosagen Cell Factory OU ¨) maintained in chemically
deﬁned serum-free media (Invitrogen, Gibko) was used. Transfection was
performed by electroporation (230 V and 975 mF) of 6 × 10
6 cells with
1 mg of expression plasmid containing the coding region of hCGa and
either the wild-type or one of the hCGb mutated variants, or one of the
subunits alone. Forty-eight hours after the transfection, cell-conditioned
media were collected and frozen at 2808C until being subjected to an
ELISA immunoassay,bioassayof hCG function and co-immunoprecipitation
of FLAG-tagged hCGb for the deglycosylation assay.
Co-immunoprecipitation and enzymatic
deglycosylation of hCGb variants
‘High yield’ FLAG-tagged hCGb variants were precipitated using 300 mlo f
CHOEBNALT85 cell-conditioned medium and applying a FLAG-Tagged
Protein Immunoprecipitation Kit (Sigma) as described above. For the en-
zymatic deglycosylation assay, 2 ml of precipitated hCGb samples were
denatured and treated either with endoglycosidase H (Endo H) or N-
glycosidase F (PNGase F) (New England BioLabs, Hitchin, UK) as per
the manufacturer’s instructions. The deglycosylation reactions were incu-
bated at 378C for 3 h and subsequently resolved on 4–12% gradient
NuPAGE Bis-Tris polyacrylamide gels (Invitrogen) and detected using
the anti-FLAG antibody as described above. For untreated control reac-
tions, the samples were processed similarly but without the addition of
the deglycosylation enzymes.
CRE-luciferase reporter gene bioassay of
hCG function
The human embryonic kidney 293 (HEK293) (American Type Culture
Collection) cell-line stably transfected with the human LH/CG receptor
(HEK-hLHR) was maintained in T75 ﬂasks in DMEM supplemented with
10% fetal bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin
(Sigma) and 0.5 mg/ml geneticin (Invitrogen, Gibco).
Following the replacement of the medium with DMEM without antibio-
tics, serum or PhenolRed, the HEK-hLHR cells were transfected with a
pADNeo2C6-BGL plasmid (kindly provided by Axel Themmen, Erasmus
MC, The Netherlands) containing the cAMP-responsive (CRE) ﬁreﬂy luci-
ferase reporter gene using Lipofectamine 2000 (Invitrogen) according to
the manufacturer’s protocol. The following day the medium was
removed and cells were stimulated with 100 ml of serially diluted cell-
conditioned medium containing CHOEBNALT85-expressed ‘high yield’
wild-type or mutant hCG adjusted for concentration of hCG heterodimer
measured with ELISA. Stimulation with a wild-type hCG b-subunit or
a-subunit only was used as a negative control. After 5–6 h stimulation
at 378C, 100 ml of buffer from SteadyliteTM plus Reporter Gene Assay
System (PerkinElmer, MA) was added. Plates were shaken in the dark
for 10 min and the CRE-luciferase activity determined using the
plate-reading luminometer (Victor, PerkinElmer-Wallac). For calculation
of the dosage response, CRE-luciferase activity values were normalized
to values of unstimulated cells. All reactions were in triplicate and experi-
ments were repeated ﬁve times. The EC50 values (+SD) (EC50 is deﬁned
as the concentration of the hormone required to produce 50% of the
maximal response) were estimated using the GraphPad Prism 5 software
and statistical signiﬁcance was calculated using a paired t-test.
Analysis of hCGb mutations 383Results
Prevalence of hCGb p.Arg8Trp, p.Val56Leu
and p.Pro73Arg substitutions
Two of the studied substitutions CGB5 p.Val56Leu (rs72556325) and
CGB8 p.Arg8Trp (rs72556341) were each identiﬁed in a single hetero-
zygous RM patient among the full screened Northern-European
sample set (Estonian, Finnish, Danish, n ¼ 1086; RM cases/controls,
n ¼ 655/431) (Table II). The carrier of the CGB5 p.Val56Leu mutation
was a Finnish male partner of a couple suffering from secondary RM
(three consecutive miscarriages after a live birth) (Rull et al., 2008b).
The carrier of the CGB8 p.Arg8Trp mutation was an Estonian male
partner of a woman with a series of unexplained RMs (Supplementary
data, Text S2). The mutation was inherited by one of two genotyped
children of the mutation carrier (Table II).
The CGB8 p.Pro73Arg mutation (rs72556345) was identiﬁed with
a similar carrier frequency (0.46%) among RM (3/655) and control
(2/431) individuals. The ﬁve heterozygous mutation carriers repre-
sented one Estonian (female partner) and two Danish (one female
and one male partner) RM patients and two Danish fertile male part-
ners with no documented miscarriages (Table II; Supplementary data,
Text S2). The CGB8 p.Pro73Arg mutation was inherited by two
live born children (Danish couples with no miscarriages) out of
seven available for genotyping (Table II).
The overall prevalence of the identiﬁed hCG beta missense mutations
in RM patients (5/655, 0.76%) was higher compared with controls
(2/431, 0.46%). The overall inheritance of the studied mutations was
slightly lower than expected by chance (50%)-altogether three out of
nine genotyped children (33%) were mutation carriers.
Positional context, evolutionary conservation
and computational structural analysis of
targeted hCGb substitutions
All three hCGb missense mutations under study are located immedi-
ately next to disulﬁde bond-forming cysteins (Cys9, Cys57 and Cys72;
Fig. 1A). The positions of point mutations in the hCGb protein suggest
that they are unlikely to affect hormone glycosylation sites or to direct-
ly alter the receptor-binding regions of the b-subunit. Instead,
Figure 1 Structural and evolutionary context of non-synonymous mutations in the hCGb protein. (A) Amino acid sequence of a signal peptide (20
aa) and mature protein (145 aa) of identical hCGb encoded by CGB5 and CGB8 genes (NCBI; NP_149032.1 for CGB5, NP_149439.1 for CGB8). Six
disulﬁde bonds found in the crystal structure of the hCGb protein (Lapthorn et al., 1994) are drawn with lines connecting respective disulﬁde bond-
forming cysteine residues (orange letters). Glycosylation sites are marked by asterisks. Regions interacting with the LH/CG receptor have been iden-
tiﬁed by extrapolating the structural model for FSH receptor (Fan and Hendrickson, 2005) and are indicated on the blue background. The positions
Arg8, Val56 and Pro73 in hCGb, targeted in this study have been indicated with an orange background. (B) Three-dimensional (3D) structure of the
assembled hCG molecule based on Protein Data Bank (PDB; http://www.pdb.org) entry 1hcn. The structure of the hCG a-subunit is depicted in
blue, b-subunit in pink and disulﬁde bonds in yellow. The side-chains of amino acids Arg8, Val56 and Pro73 in hCGb are shown in the space-ﬁlling
representation. (C) Protein sequence logos surrounding hCGb positions Arg8, Val56 and Pro73 (in red boxes). The letter size is proportional to the
degree of conservation among hCGb homologs (Supplemental Data, Table SI and Fig. S2).
384 Nagirnaja et al.positions Arg8 and Val56 are involved in the central cystine knot struc-
ture essential for the hCGb folding and the heterodimer assembly
(Fig. 1B). Valine at position 56 is fully conserved among hCGb homo-
logs from mammals to ﬁshes, whereas position 8 is less constrained
with Leu being even more favored than Arg (Fig. 1C; Supplementary
data, Table SI and Fig. S2). Position Pro73 is incorporated in a
stable turn of the protein loop 3 that does not directly associate
with the hCG a-subunit or the LH/CG receptor (Fig. 1A and B).
Therefore, greater variation in amino acid usage is tolerated at position
73. Although Pro is the most frequent choice at this site, hCGb
protein homologs also frequently have Arg or Leu (Fig. 1C).
In addition, a computational structural analysis was applied to esti-
mate the SAS for the hCGb positions 8, 56 and 73 using the published
crystal structure of the hCG dimer (Protein Data Bank; 1hcn)
(Lapthorn et al., 1994). Position Val56, located in the cystine knot
structure, is largely buried within the hCGa/b heterodimer
complex with only 3% exposed to the solvent compared with 46%
in the case of the unassembled b-monomer (Fig. 2). Therefore,
amino acid substitutions at this position might be expected to have
a minor effect on the b-subunit alone but a more pronounced
effect on the hCGa/b complex. In particular, the replacement of
valine with leucine, which has a larger side-chain, could presumably
hinder the formation/stability of the heterodimer.
The hCGb position Pro73 is localized within the solvent-exposed
hCGb loop and does not directly interact with the hCG a-subunit.
Thus, the solvent accessibility of Pro73 remains unaffected after the
formation of the hCGa/b complex (Fig. 2). Although the hCGb pos-
ition Arg8 is located in the structurally conserved cystine knot of
hCGb, the surface of position 8 also remains exposed to the
solvent upon interaction with the a-subunit (47% in hCG versus
61% in hCGb; Fig. 2). Therefore, neither of these two mutations
would be expected to have a major effect on the a/b assembly.
MD simulations
The impact of b-subunit mutations on the dynamics of the hCG het-
erodimer was explored by performing 30 ns MD simulations for the
wild-type and mutant hCGs. MD simulations showed that the a/b
heterodimer is very dynamic, partly because of the large amount of
loops ( 50% of the residues). Interestingly, mutations of the
b-subunit appeared to have an impact on the a-chain as well
(Table III). To explore the position-dependent ﬂexibility of the hCG
heterodimer, root-mean-square ﬂuctuations (RMSF) of Ca carbons
with respect to the averaged and minimized structures (in the 10–
30-ns interval) were computed for all four hCG variants (Fig. 3). In
general, the observed changes did not reveal dramatic structural rear-
rangements. However, the data in Fig. 3, supported by the structural
analysis of MD-generated structures (Supplementary data, Text S3 and
Fig. S4) show that all three mutants exhibited less ﬂexibility than the
wild-type hCG. This can be explained by the formation of additional
hydrogen bonds between the spatially neighboring loops (notably in
p.P73R; Supplementary data, Text S3), and the increase of the
amount of b-strands in the structure in the case of the p.V56L and
p.R8W mutations. Overall, compared with the wild-type, the
p.V56L assembly behaved most differently, followed by p.P73R,
while the behavior of the p.R8W differed the least.
hCGb p.Val56Leu and p.Pro73Arg
substitutions affect assembly of the hCGa/b
dimer in in vitro assays
Co-immunoprecipitation techniques were employed to assess the
effect of hCGb p.Arg8Trp, p.Val56Leu and p.Pro73Arg mutations
on the assembly of the hCG dimer. FLAG-tagged wild-type and
mutant hCG b-subunits were co-expressed with un-tagged a-subunits
in CHO cell lines. Using the FLAG-tagged epitope, secreted-free
hCGb monomers and heterodimeric hCG were immunoprecipitated
from the cell culture media and subjected to western blot testing
for detection with either the anti-FLAG antibody, which probed for
both hCGb monomers and assembled a/b heterodimers (Fig. 4A
and C), or via antiserum against the hCG a-subunit that speciﬁcally
visualizes the assembled heterodimer hormone only (Fig. 4B). Under
non-reducing conditions a  47 kDa hCG heterodimer was identiﬁed
with both antiserum against hCGa and anti-FLAG antibody (Fig. 4A
and B), whereas a  34 kDa hCGb monomer was visualized via the
anti-FLAG antibody in reducing and non-reducing conditions (Fig. 4A
and C). In case of the p.Val56Leu substitution, the proportion of
b-subunits incorporated into a/b heterodimers relative to the
freely retained b-monomers was notably reduced compared with
the wild-type (Fig. 4A), indicating a decreased capability of
p.Val56Leu b-subunits to assemble into the heterodimer.
Figure 2 Solvent accessible surfaces of hCGb Arg8, Val56 and
Pro73 in hCGb alone and in hCGa/b.( A) The percentage of
solvent accessible surface areas in hCGb alone and in the intact
hCGa/b complex. (B) Visual representation of SAS areas of hCGb
Arg8, Val56 and Pro73 residues in the hCGa/b complex using Vor-
oprot (Olechnovic ˇ et al., 2011). Solvent accessible surface areas are
displayed as a mesh.
........................................................................................
Table III Ca atom root-mean-square deviation
(RMSD) (nm) between the X-ray structure and the
10–30 ns averaged/minimized structures resulting
from the MD simulations.
aba /b
WT 0.253 0.287 0.303
p.R8W 0.179 0.304 0.278
p.V56L 0.266 0.326 0.346
p.P73R 0.304 0.288 0.320
The values (nm) are shown separately for the individual subunits and for the
assembled hCG heterodimer.
Analysis of hCGb mutations 385The hCGb p.Pro73Arg mutant gave rise to two alternative hCGb
isoforms, one corresponding to the molecular weight of the wild-type
hCGb ( 34 kDa) and an additional variant with  2 kDa lower
molecular weight (Fig. 4A). Both isoforms were being assembled
into the hCG dimer with approximately equal efﬁciency (Fig. 4A and
B). In the case of hCGb p.Arg8Trp substitution, the applied SDS–
PAGE and western blot analysis did not reveal detectable differences
in the fraction of free hCGb or in the assembly of intact hCG com-
pared with the wild-type variant (Fig. 4).
Several additional high-molecular-weight protein complexes were
visualized by the anti-FLAG antibody under non-reducing experimen-
tal conditions (Fig. 4A). As these bands were neither visualized via
antisera against the a-subunit incorporated into intact hCG (Fig. 4B)
nor detected under reducing conditions disrupting all disulﬁde bonds
Figure 3 RMSF of the Ca carbons with respect to the average MD structures. Wild-type and mutated residues at positions under study are indi-
cated with ﬁlled circles and labels. Secondary structure elements (a-helices or b-strands) in the WT X-ray structure are represented as black bars
along the horizontal axis.
Figure 4 Co-immunoprecipitation and western blot analysis of FLAG-tagged hCGb variants co-expressed with hCGa in CHO cells. FLAG-tagged
hCGb monomers and associated complexes were immunoprecipitated from CHO cell culture media using anti-FLAG antibody-conjugated beads and
separated by SDS–PAGE under non-reducing (A and B) or reducing (C) conditions. (A and C) Free and heterodimeric assembled FLAG-tagged
hCGb was detected using the anti-FLAG antibody. (B) A heterodimeric hCG was speciﬁcally visualized using antiserum to the hCG a-subunit.
Bands corresponding to the heterodimeric hCG and unassembled hCGb monomers are indicated by arrowheads; bands corresponding to
b-subunit-speciﬁc multimeric complexes are indicated with a bracket. The data are drawn from the same experiment and they are representative
of three independent co-immunoprecipitation experiments. An alternative a/b complex with the hCGb conformational isoform caused by the
p.Pro73Arg mutation is indicated by an asterisk.
386 Nagirnaja et al.(Fig. 4C), we speculate that they may represent covalent multimeric
hCGb-speciﬁc complexes shown to be secreted from the cells, espe-
cially in the presence of mutations that affect the b-subunit folding
pathway (Bedows et al., 1994; Feng et al., 1995, 1996).
In the SDS–PAGE run under reducing conditions that causes dis-
sociation of hCG dimers and disruption of disulﬁde bonds, all tested
hCGb variants collapsed into one major ( 34 kDa) and one minor
( 31 kDa) isoform (Fig. 4C), previously shown to contain either
two or one N-linked oligosaccharide chain, respectively (Matzuk
et al., 1987). No evidence of the effect of the studied substitutions
on the glycosylation pattern of the hCGb protein was seen in the
enzymatic deglycosylation assay using either Endo H or PNGase F
deglycosidases (Supplementary data, Fig. S5).
Quantitative immunoassays conﬁrm the
deﬁcient assembly of intact hCG in the case
of the hCGb p.Val56Leu variant
The efﬁciency of hCG dimerization was estimated using the ratio of
assembled intact hCG to the total amount of the secreted hCGb
subunit in the cell culture media of the transfected CHO cells. In
case of the hCGb p.Val56Leu mutation, on average only 10% of
dimers were assembled compared with the wild-type ( ¼ 100%) (Stu-
dent’s t-test, P ¼ 0.014) (Fig. 5). The outcome of the immunoassay is
consistent with the co-immunoprecipitation results on the p.Val56Leu
mutation reported above. For hCGb mutants p.Arg8Trp and
p.Pro73Arg, the fraction of the secreted hCG b-subunit assembled
into intact hormone did not signiﬁcantly differ from the wild-type.
The hCGb p.Val56Leu variant exhibits an
increased bioactivity upon binding to the
human LH/CG receptor in the in vitro
bioassay
The QMCF technology was applied to produce ‘high yield’ intact hCG
reaching a 10 times higher concentration in the medium compared
with the expression of the hCG heterodimer with the conventional
transient co-transfection of the a- and b-subunits. Serial dilutions of
the CHOEBNALT85 cell-conditioned media adjusted for the concen-
tration of heterodimeric hCG were used to stimulate HEK-hLHR cells,
and the cAMP signaling response was measured. The cAMP response
to stimulation with CGB5 p.Val56Leu was signiﬁcantly more sensitive
than to the wild-type hCG (Fig. 6), exhibiting a half-maximal response
EC50 of 2.50+0.81 pg/ml compared with the wild-type hCG EC50 of
11.41+2.32 pg/ml (P , 0.0013). No signiﬁcant differences were
observed between the wild-type hCGb and variants carrying either
mutation CGB8 p.Arg8Trp or CGB8 p.Pro73Arg (EC50 of 13.51+
3.47 pg/ml, P ¼ 0.131; 8.35+3.54 pg/ml, P ¼ 0.053, respectively)
(Fig. 6). The results were conﬁrmed by the same experiments per-
formed on CHO cells transiently transfected with the human LH/
CG receptor (data not shown).
Discussion
We have previously reported singleton heterozygous carriers of muta-
tions CGB5 p.Val56Leu and CGB8 p.Arg8Trp, p.Pro73Arg among RM
patients (Rull et al., 2008b). In the current study, we addressed the
effect of the identiﬁed substitutions on hCG synthesis and function
by combining in silico comparative genomics and computational struc-
tural analysis with in vitro experiments. For the mutation CGB5
Figure 5 Effect of hCGb mutations on the formation of the hCG
heterodimer as determined by immunoassays. The total b-subunit
(free b-monomers + b-subunit fraction assembled into the hCGa/
b heterodimer) in CHO cell culture media was quantiﬁed on the
Elecsys 1010 system and the quantity of assembled a/b heterodimer
only was determined with the intact hCG-speciﬁc ELISA assay. The
data points represent the measurements of duplicate independent
transfections. For each hCGb mutation, the mean ratio of the
assembled to the total b-subunits was calculated and compared
with the wild-type (¼100%). The P-value was calculated using Stu-
dent’s t-test. Circles indicate the concentration of the total
b-subunit (mIU/ml) and triangles the concentration of assembled
heterodimeric hCG (pg/ml) in the medium.
Figure 6 Bioactivity of hCGb variants measured as an hLH/CG
receptor-mediated cAMP signaling response to stimulation with the
dosage gradient of heterodimeric wild-type and mutant hCG prepara-
tions. Stimulation with wild-type hCGb or hCGa monomers was
used as a negative control. The fold response is given as a ratio of
the CRE luciferase activity to unstimulated cells. The data are the
mean+SD of ﬁve independent experiments.
Analysis of hCGb mutations 387p.Val56Leu in silico analyses predicted and cell-culture experiments
consistently conﬁrmed the effect of the substitution on the intact
hCG a/b dimer assembly, but also on the bioactivity upon binding
to the LH/CG receptor and stimulation of the cAMP response. The
CGB8 p.Pro73Arg mutation was found to alter the hCGb conform-
ation and the heterodimer assembly. For the third mutation studied
(CGB8 p.Arg8Trp) the chosen experimental design did not detect
major structural or functional consequences, which was in agreement
with the computational predictions.
Among the three studied substitutions, hCGb p.Val56Leu had a
substantial effect on the assembly of the bioactive hormone. The
co-immunoprecipitation assay and quantitative immunoassays demon-
strated that only 10% of the secreted hCGb carrying the p.Val56Leu
mutation was incorporated into the intact heterodimeric hCG com-
pared with the wild-type. The effect of the p.Val56Leu substitution
can be explained by its location in the core part of the hCGb structure
immediately next to Cys57, which forms one of the disulﬁde bonds
(Cys9-Cys57) in the cystine knot (Fig. 1A) (Lapthorn et al., 1994).
The cystine knot is a highly conserved structural feature not only in
hCG a- and b-subunits, but also among growth factors such as trans-
forming growth factor-b2, NGF and platelet-derived growth factor-BB
(Murray-Rust et al., 1993; Lapthorn et al., 1994). Disruption of the
Cys9-Cys57 bond has previously been shown to give rise to folding
and assembly deﬁcient hCGb protein (Bedows et al., 1994; Mishra
et al., 2003). Although not directly involved in the disulﬁde bond for-
mation, Val56 becomes almost completely buried due to the inter-
action with the a-subunit when the intact hCG is formed (Figs 1B
and 2). Therefore, it was expected that any substitution at this position
would destabilize the assembled hormone. The high evolutionary con-
servation of Val56 among hCGb homologs (Fig. 1C) (including human
TSHb and LHb; except for Thr in FSHb) further underlines its import-
ance in the formation of a functional hormone (Pierce and Parsons,
1981).
Surprisingly, in addition to posing a hindrance on heterodimer for-
mation, the p.Val56Leu mutation also modiﬁed the bioactivity of the
assembled hormone (Fig. 6). The half-maximal response of the het-
erodimer carrying the p.Val56Leu mutation was increased 4.6-fold
compared with the wild-type when binding to the LH/CG receptor
and stimulating the cAMP response. It has been previously observed
that in addition to its role in the interaction of the subunits the
region involving the Cys9-Cys57 bond also exhibits the highest
potency toward the LH/CG receptor (Mishra et al., 2001). The MD
simulations with the hCGb p.Val56Leu mutation predicted slight
changes in the structural conformation of the hCGb and altered
dynamics for both hCG subunits and the heterodimer (Table III; Sup-
plementary data, Text S3 and Fig. S4), providing a possible explanation
for the increased potency of the assembled hormone. As a conse-
quence, the shortage of the produced dimeric hormone (10%
compared with the wild-type) may be partly or fully compensated
for by its increased bioactivity.
The CGB8 p.Pro73Arg mutation is located near the top of the
hCGb loop 3 not interacting directly with the a-subunit or the LH/
CG receptor (Fig. 1A and B). Interestingly, this substitution resulted
in the formation of two alternative conformational variants of hCGb
(wild-type and  2 kDa smaller isoforms). These two b-monomers
have a similar glycosylation pattern (Supplementary data, Fig. S5),
were secreted in approximately equal amounts and were both
assembly-competent (Fig. 4B). Pro73 is located next to Cys72,
which forms one of the ﬁve disulﬁde bonds, Cys23–Cys72. Disruption
of this bond has been demonstrated to affect the folding pathway of
the b-subunit by destabilizing a conformational intermediate of the
hCGb protein. Consequently, an additional isoform lacking the
Cys23–Cys72 bond and exhibiting a difference of 2 kDa in size on
SDS–PAGE was secreted into the medium (Bedows et al., 1993,
1994). It has also been reported that the substitution of Pro73 with
Gly slows down the ﬁnal folding of the hCGb subunit (Feng et al.,
1996). Although changes in the quality of disulﬁde bonding and kinetics
of the hCGb folding may also be speculated in the case of the
p.Pro73Arg mutation, it was not addressed directly in the current
study. Importantly, the overall functional characteristics of the
p.Pro73Arg heterodimeric isoforms remain comparable with the wild-
type (Fig. 6), pointing to the functional neutrality of this mutation.
Concurrently, the p.Pro73Arg mutation can be found with the same
carrier frequency among RM patients and controls (0.46%) and it is
inherited by two out of seven children of the p.Pro73Arg mutation
carriers (Table II).
The position of the third mutation, hCGb p.Arg8Trp is located in
the conserved hCGb cystine knot structure but it is largely exposed
to the solvent and exhibits low evolutionary conservation (Figs 1B
and C and 2). No major structural or functional effects were observed
for this mutation in performed wetlab and in silico experiments.
It is noteworthy that, apart from apparently population-speciﬁc
p.Val79Met (4.2% allele frequency in Omaha, USA) (Miller-Lindholm
et al., 1999; Jiang et al., 2004), only a few other rare missense muta-
tions have been identiﬁed in the CGB5 and CGB8 genes worldwide. In
CGB8, p.Val29Ile was found in Estonians (9 heterozygotes/194 sub-
jects) and Finns (1 heterozygote/185 individuals) (Rull et al., 2008b).
In CGB5, p.Arg6Gln was identiﬁed in a single Han Chinese (among
25 screened subjects) and p.Asp117Ala in two African Mandekalu
(n ¼ 23) samples (Hallast et al., 2005), but no clinical information is
available on these mutation carriers. The current study identiﬁed het-
erozygous carriers of rare hCGb mutations among ﬁve North-
European RM patients and two controls with proven fertility. Lack
of common missense mutations in the most abundantly expressed
genes CGB5 and CGB8, which contribute 62–82% to the pool of
hCGb mRNA (Miller-Lindholm et al., 1997; Rull and Laan, 2005),
emphasizes the requirement of full transcription and production of
functional protein from these genes for a successful pregnancy
outcome. Interestingly, in the studied families, the wild-type CGB8
gene variants had a small preference to be inherited by the next gen-
eration (only three heterozygous mutation carriers out of nine children
tested) (Table II). Furthermore, no individuals homozygous for any
hCGb mutations have been identiﬁed so far, which may indicate
either an insufﬁcient sample size in the conducted studies or that
such genotypes result in a complete pregnancy failure. In summary,
the accumulated data indicate that only mutations with neutral or
mild functional consequences might be tolerated in the major hCG
beta coding genes CGB5 and CGB8.
Supplementary data
Supplementary data are available at http://molehr.oxfordjournals.org/
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